Targets › CAMPATH1
1 program from 1 company in 1 trial: 1 Phase 2; Genitourinary; next expected readout Jun 2034.
Open in Phaseline: the race on CAMPATH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Johns Hopkins University | Monoclonal Antibody (Humanized Anti-CD52) Anti-CD52 monoclonal antibody for immunosuppression | CAMPATH1 | Phase 2 | Amputation | Jun 2034 |
Amputation (1)
mixed (1)
Johns Hopkins University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.